公开(公告)号：US20250011878A1

公开(公告)日：2025-01-09

申请号：US18711937

申请日：2022-11-22

Applicant: ITALFARMACO SPA

Inventor： Gianluca FOSSATI ,  Chiara RIPAMONTI ,  Christian STEINKÜHLER

IPC: C12Q1/6886

Abstract: The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as “gene expression signatures”, in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.